Latest technologies for the enhancement of antibody affinity.
High affinity antibodies are crucial both for the discovery and validation of biomarkers for human health and disease and as clinical diagnostic and therapeutic reagents. This review describes some of the latest technologies for the design, mutation and selection of high affinity antibodies that provide a paradigm for molecular evolution of a far wider range of proteins including enzymes. Strategies include both in vivo and in vitro methods and embrace the latest concepts for antibody display and selection. Specifically, affinity enhancement can be tailored to the target-binding surface, typically the complementary determining region (CDR) loops in antibodies, whereas enhanced stability, expression or catalytic properties can be affected by selected changes to the core protein scaffold. Together, these technologies provide a rapid and powerful strategy to drive the next generation of protein-based reagents for numerous clinical, environmental and agribusiness applications.
Wark
Kim L
KL
CRC for Diagnostics at CSIRO Molecular and Health Technologies, 343 Royal Parade, Parkville 3052, Australia. kim.wark@csiro.au
Hudson
Peter J
PJ
D000818:Animals; D000915:Antibody Affinity / Q000187:drug effects* / Q000235:genetics; D015195:Drug Design; D006801:Humans; D016296:Mutagenesis; D015202:Protein Engineering